MARQ 0.0.1

data/install_scripts/GEO/series/GSE5070.yaml

@@ -0,0 +1,25 @@
+--- 
+:description: |-
+  The role of the S. cerevisiae Yap4 transcription factor in the response to hyperosmolarity was investigated in two ways. Firstly, to assess the overall response of the yap4 deleted strain genome wide analysis upon a mild upshift in osmolarity was compared to the same response in the wt strain. Secondly, in order to identify genes whose osmo-expression is differentially regulated in the mutant strain (ie potential Yap4 target genes) the relative abundance of cDNAs of the wt and yap4 mutant strain obtained upon an osmotic upshift were directly compared by microarray analysis.
+  Keywords: Mutant Stress Response
+:title: Role of Yap4 in Yeast Osmotic Stress Response
+:arrays: 
+  GSM114156: 
+    condition: yap4 OsmoticStress
+  GSM114157: 
+    condition: yap4 OsmoticStress
+  GSM114137: 
+    condition: wt OsmoticStress
+  GSM114139: 
+    condition: wt OsmoticStress
+  GSM114153: 
+    condition: wt vs yap4 OsmoticStress
+  GSM114142: 
+    condition: wt OsmoticStress
+  GSM114154: 
+    condition: wt vs YAP4 wt vs yap4 OsmoticStress
+  GSM114143: 
+    condition: wt vs YAP4 wt vs yap4 OsmoticStress
+  GSM114155: 
+    condition: yap4 OsmoticStress
+:platform: GPL537

data/install_scripts/GEO/series/GSE5238.yaml

@@ -0,0 +1,31 @@
+--- 
+:description: |-
+  In Saccharomyces cerevisiae growth, size control and cell cycle progression are strictly coordinated and regulated according to the nutritional conditions. In particular, ribosome biogenesis appears a key event in this regulatory network. SFP1 encodes a zinc-finger protein promoting the transcription of a large cluster of genes involved in ribosome biogenesis. It has been suggested that Sfp1 is a cell size modulator acting at Start. To better study the regulatory role of Sfp1 and its putative involvement in cell size and cycle control, we analysed the behaviour of an sfp1 null mutant strain and of an isogenic reference strain growing in chemostat cultures. This approach allowed us to analyze both strains at the same specific growth rate, thus eliminating the secondary effects due to the slow growing phenotype that the sfp1 null mutant shows in shake flask. We studied glucose(anaerobic)- and ethanol(aerobic)-limited cultures, as paradigms of two different metabolic states. Major alterations of the transcriptional profile were observed during growth on glucose, while no significant differences were observed when comparing ethanol growing cultures. In particular, in the former growth condition, Sfp1 appears involved in the control of ribosome biogenesis but not of ribosomal protein gene expression.
+  Keywords: global transcriptional profile, genetic modification, ribosome biogenesis
+:title: SFP1 dependent transcription
+:arrays: 
+  GSM118589: 
+    treatment: sfp1 delta EtOH-lim
+  GSM118590: 
+    treatment: sfp1 delta Glu-lim
+  GSM118591: 
+    treatment: sfp1 delta Glu-lim
+  GSM118592: 
+    treatment: sfp1 delta Glu-lim
+  GSM118581: 
+    treatment: CENPK113.7D EtOH-lim
+  GSM118582: 
+    treatment: CENPK113.7D EtOH-lim
+  GSM118583: 
+    treatment: CENPK113.7D EtOH-lim
+  GSM118584: 
+    treatment: CENPK113.7D Glu-lim
+  GSM118585: 
+    treatment: CENPK113.7D Glu-lim
+  GSM118586: 
+    treatment: CENPK113.7D Glu-lim
+  GSM118587: 
+    treatment: sfp1 delta EtOH-lim
+  GSM118588: 
+    treatment: sfp1 delta EtOH-lim
+:platform: GPL90

data/install_scripts/GEO/series/GSE5267.yaml

@@ -0,0 +1,55 @@
+--- 
+:description: |-
+  Tetracyclines are effective but slow-acting antimalarial drugs whose mechanism of action remains uncertain. To characterize the antimalarial mechanism of tetracyclines, we evaluated their stage-specific activities, impacts on parasite transcription, and effects on two predicted organelle targets, the apicoplast and the mitochondrion, in cultured Plasmodium falciparum. Antimalarial effects were much greater after two 48-h life cycles than after one cycle, even if the drugs were removed at the end of the first cycle. Doxycycline-treated parasites appeared morphologically normal until late in the second cycle of treatment but failed to develop into merozoites. Doxycycline specifically impaired the expression of apicoplast genes. Apicoplast morphology initially appeared normal in the presence of doxycycline. However, apicoplasts were abnormal in the progeny of doxycycline-treated parasites, as evidenced by a block in apicoplast genome replication, a lack of processing of an apicoplast-targeted protein, and failure to elongate and segregate during schizogeny. Replication of the nuclear and mitochondrial genomes and mitochondrial morphology appeared normal. Our results demonstrate that tetracyclines specifically block expression of the apicoplast genome, resulting in the distribution of nonfunctional apicoplasts into daughter merozoites. The loss of apicoplast function in the progeny of treated parasites leads to a slow but potent antimalarial effect.
+  Keywords: Plasmodium falciparum treated with Doxycycline
+:title: Tetracyclines Specifically Target the Apicoplast of the Malaria Parasite Plasmodium falciparum
+:arrays: 
+  GSM119447: 
+    condition: doxy 25h
+  GSM119436: 
+    condition: control 30h
+  GSM119437: 
+    condition: control 35h
+  GSM119448: 
+    condition: doxy 30h
+  GSM119450: 
+    condition: doxy 40h
+  GSM119438: 
+    condition: control 40h
+  GSM119449: 
+    condition: doxy 35h
+  GSM119440: 
+    condition: control 50h
+  GSM119451: 
+    condition: doxy 45h
+  GSM119439: 
+    condition: control 45h
+  GSM119441: 
+    condition: control 55h
+  GSM119430: 
+    condition: control 0h
+  GSM119452: 
+    condition: doxy 50h
+  GSM119431: 
+    condition: control 5h
+  GSM119442: 
+    condition: doxy 0h
+  GSM119453: 
+    condition: doxy 55h
+  GSM119443: 
+    condition: doxy 5h
+  GSM119432: 
+    condition: control 10h
+  GSM119444: 
+    condition: doxy 10h
+  GSM119433: 
+    condition: control 15h
+  GSM119434: 
+    condition: control 20h
+  GSM119445: 
+    condition: doxy 15h
+  GSM119446: 
+    condition: doxy 20h
+  GSM119435: 
+    condition: control 25h
+:platform: GPL3983

data/install_scripts/GEO/series/GSE5281.yaml

@@ -0,0 +1,492 @@
+--- 
+:arrays: 
+  GSM238874: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238817: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119639: 
+    tissue: hippocampus
+    disease: control
+  GSM238845: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238846: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119668: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238818: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238847: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238790: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119669: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238819: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238875: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238791: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238848: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238763: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119640: 
+    tissue: hippocampus
+    disease: control
+  GSM238877: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238792: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119641: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM119670: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238793: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119642: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238820: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238794: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119671: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM119643: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238963: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119672: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238821: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119644: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238795: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119615: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119616: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM238851: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119673: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238822: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119645: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238796: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238797: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119674: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238823: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119617: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119675: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238824: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119646: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM119618: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119619: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119676: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM119647: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238825: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238798: 
+    tissue: entorhinal cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238854: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238799: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119677: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238826: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119648: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM119678: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238827: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119649: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238855: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238856: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119620: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119679: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238857: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119621: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119650: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238941: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238858: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119622: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM238800: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119651: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238942: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119623: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM238943: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119652: 
+    tissue: medial temporal gyrus
+    disease: control
+  GSM238801: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119680: 
+    tissue: primary visual cortex
+    disease: control
+  GSM119653: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238944: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238802: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119624: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119681: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238860: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119654: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238945: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238803: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119625: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119682: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238946: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119655: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238804: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119626: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM238861: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119683: 
+    tissue: primary visual cortex
+    disease: control
+  GSM119627: 
+    tissue: entorhinal cortex
+    disease: control
+  GSM119656: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238947: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238805: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238862: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119684: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238863: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238834: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238948: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238806: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119628: 
+    tissue: hippocampus
+    disease: control
+  GSM119685: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238807: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119629: 
+    tissue: hippocampus
+    disease: control
+  GSM119686: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238835: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238949: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119657: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238808: 
+    tissue: hippocampus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238864: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119687: 
+    tissue: primary visual cortex
+    disease: control
+  GSM119658: 
+    tissue: posterior cingulate
+    disease: control
+  GSM119659: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238837: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238865: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119688: 
+    tissue: primary visual cortex
+    disease: control
+  GSM238809: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119630: 
+    tissue: hippocampus
+    disease: control
+  GSM238838: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238867: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119631: 
+    tissue: hippocampus
+    disease: control
+  GSM238839: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238951: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119632: 
+    tissue: hippocampus
+    disease: control
+  GSM238868: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119660: 
+    tissue: posterior cingulate
+    disease: control
+  GSM119633: 
+    tissue: hippocampus
+    disease: control
+  GSM119661: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238952: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238810: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238840: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238811: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119634: 
+    tissue: hippocampus
+    disease: control
+  GSM238953: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119662: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238841: 
+    tissue: posterior cingulate
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119663: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238812: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119635: 
+    tissue: hippocampus
+    disease: control
+  GSM238870: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238955: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119664: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238813: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238871: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119636: 
+    tissue: hippocampus
+    disease: control
+  GSM238842: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119665: 
+    tissue: posterior cingulate
+    disease: control
+  GSM238843: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238872: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119666: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238815: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119637: 
+    tissue: hippocampus
+    disease: control
+  GSM119667: 
+    tissue: superior frontal gyrus
+    disease: control
+  GSM238844: 
+    tissue: superior frontal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM238816: 
+    tissue: medial temporal gyrus
+    disease: "Alzheimer\xE2\x80\x99s disease"
+  GSM119638: 
+    tissue: hippocampus
+    disease: control
+  GSM238873: 
+    tissue: primary visual cortex
+    disease: "Alzheimer\xE2\x80\x99s disease"
+:description: "Information about the genes that are preferentially expressed during the course of Alzheimer\xE2\x80\x99s disease (AD) could improve our understanding of the molecular mechanisms involved in the pathogenesis of this common cause of cognitive impairment in older persons, provide new opportunities in the diagnosis, early detection, and tracking of this disorder, and provide novel targets for the discovery of interventions to treat and prevent this disorder. Information about the genes that are preferentially expressed in relationship to normal neurological aging could provide new information about the molecular mechanisms that are involved in normal age-related cognitive decline and a host of age-related neurological disorders, and they could provide novel targets for the discovery of interventions to mitigate some of these deleterious effects.\n\
+  Aim 1. Collect brain samples from three Alzheimer\xE2\x80\x99s Disease Centers (ADCs) for subsequent gene expression profiling. Individuals will be stratified with respect to diagnostic groups (using both clinical and neuropathological criteria), age groups, and APOE genotype. 150 individual brains will be sampled from the Arizona ADC, the Duke University ADC, and the Washington University ADC. Miniscule sample sizes (200 um of sectioned tissue) from six brain regions that are histopathologically or metabolically relevant to AD and aging will be collected, ensuring that this proposal does not deplete the national resource. Frozen and fixed samples will be sent to Phoenix, sectioned in a standardized fashion, and then returned. Aim 2. Tissue heterogeneity will be eliminated prior to expression profiling by performing laser capture microscopy on all brain regions. Aim 3. Expression profile LCM-captured cells on the Affymetrix U133 Plus 2.0 array (~55,000 transcripts), and quickly provide these data to the community at large. Aim 4. Identify pathogenic cascades related to each of the clinico-pathologic correlates using unsupervised and supervised analyses coupled with a hypothesis-driven approach. Aim 5. Validation of the expression correlates at the protein and functional levels.\n\
+  Scientific progress in the last few years has improved our understanding of AD and raised the hope of identifying treatments to halt the progression and prevent the onset of this disorder. For instance, researchers have begun to characterize the cascade of molecular events which lead to the major histopathological features of the disorder: neuritic plaques, which contain extra-cellular deposits of amyloid beta-peptides (Abeta); neurofibrillary tangles, which contain the hyperphosphorylated form of the intracellular, microtubule-associated protein, tau; and a loss of neurons and synapses. These molecular events provide targets for the development of promising new treatments. For example, A-beta has been postulated to trigger a cascade of events that are involved in the pathogenesis of AD. This proposal hopes to provide new information about the genes that are preferentially expressed in the development of AD histopathology, including the over-expression of APP, amyloid-induced neurotoxicity, and hyperphosphorylation of tau, as well as bring clarity to the metabolic abnormalities that seem to play a role in dementia and AD development and pathology.\n\
+  We will perform LCM on 6 brain regions with about 14 biological replicates per brain region.  The brain regions are as follows: 1) entorhinal cortex 2) hippocampus 3) medial temporal gyrus 4) posterior cingulate 5) superior frontal gyrus and 6) primary visual cortex.  We will collect layer III pyramidal cells from the white matter in each region, isolate total RNA from LCMed cell lysates, and perform double round amplification of each sample for array analysis.\n\
+  Keywords: other"
+:title: Alzheimer's disease and the normal aged brain (steph-affy-human-433773)
+:platform: GPL570